Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJan 10, 2005	Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005 General Business	View HTML Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference 20.7 KB
Toggle SummaryJan 6, 2005	Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck & Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I Other	View HTML Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers 14.3 KB
Toggle SummaryJan 5, 2005	Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at JPMorgan's 23rd Annual Healthcare Conference in San Webcasts	View HTML Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference 7.2 KB
Toggle SummaryDec 15, 2004	Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Montego Bay, Jamaica, December 15, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD) General Business	View HTML Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART 14.4 KB
Toggle SummaryNov 10, 2004	Novartis Selects Drug Candidate for Clinical Development from Protein Kinase Research Collaboration with Vertex --Novel compound, VX-322, targets key mechanisms implicated in leukemia and other cancers-- General Business	View HTML Novartis Selects Drug Candidate for Clinical Development from Protein Kinase Research Collaboration with Vertex 13 KB
Toggle SummaryNov 8, 2004	Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine - Company named Business Leader in Medical Treatment in the 2004 "Scientific American 50" - General Business	View HTML Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine 11.6 KB
Toggle SummaryNov 8, 2004	Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -- First study in HCV patients will evaluate dosing up to 14 days -- HCV	View HTML Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C 11.6 KB
Toggle SummaryNov 1, 2004	Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C -Encouraging Results Support Initiation of Phase Ib Clinical Study- HCV	View HTML Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C 13.7 KB
Toggle SummaryOct 25, 2004	Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update Company continues to achieve its financial and pipeline goals General Business	View HTML Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update 416.9 KB
Toggle SummaryOct 18, 2004	Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients -First demonstration of CRP reduction in cardiovascular patients using an oral cytokine inhibitor- Other	View HTML Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients 14.5 KB